Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03846193
Other study ID # GT005-01
Secondary ID CPPY988A12101
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date December 17, 2018
Est. completion date June 28, 2024

Study information

Verified date January 2024
Source Gyroscope Therapeutics Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open label first in human Phase I/II multicentre study of GT005 in subjects with Macular Atrophy due to AMD


Description:

This study will evaluate the safety, the dose response and efficacy (anatomical and functional visual outcomes) of three doses of GT005 administered as a single subretinal injection in genetically defined subjects with Macular Atrophy due to Age-related Macular Degeneration (AMD). Following consent, subjects will undergo a number of ophthalmic and clinical assessments to determine eligibility for inclusion in the study. Once eligibility is confirmed, subjects will be enrolled, receive treatment, and will be followed for 48 weeks, with the option to be followed for a further 4 years in long-term follow up after completing week 48. This study is terminating early due to the interim analysis demonstrating lack of treatment efficacy. No additional subjects will be randomized or dosed. The trial is not ending early because of medical problems.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 56
Est. completion date June 28, 2024
Est. primary completion date June 28, 2024
Accepts healthy volunteers No
Gender All
Age group 55 Years and older
Eligibility Inclusion Criteria: 1. Able and willing to give consent to study participation 2. Have a clinical diagnosis of GA secondary to AMD in the study eye, as determined by the Investigator, and a diagnosis of AMD in the contralateral eye (except if the subject is monocular) 3. Cohorts 1 to 6: GA lesion(s) total size in the study eye must be =1.25mm2 and =17.5mm2. Cohort 7: GA lesion(s) total size in the study eye must be =1.25mm2 4. GA lesion(s) in the study eye must reside completely within the FAF fundus image 5. Cohorts 1 to 3: BCVA of =50 letters (6/36 Snellen acuity equivalent or worse) using ETDRS charts in the study eye Cohorts 4 to 7: BCVA of =24 letters (6/95 and 20/320 Snellen acuity equivalent or better) using ETDRS charts in the study eye 6. Aged =55 years 7. Able to attend all study visits and complete the study procedures 8. Women of child-bearing potential need to have a negative urine pregnancy test within two weeks prior to receiving the drug. A pregnancy test is not required for postmenopausal women (defined as being at least 12 consecutive months without menses) or those surgically sterilised (those having a bilateral tubal ligation/bilateral salpingectomy, bilateral tubal occlusive procedure, hysterectomy, or bilateral oophorectomy) Exclusion Criteria: 1. Have evidence or history of Choroidal Neovascularisation (CNV) in the study eye. Subjects are permitted to have CNV in the fellow eye defined as either: 1. Non-exudative/sub-clinical fellow eye CNV identified at screening, or 2. Known history of fellow eye CNV with either =2 years since diagnosis or with no active treatment required in 6 months prior to screening 2. Presence of moderate/severe non-proliferative diabetic retinopathy or worse in the study eye 3. Have history of vitrectomy, sub-macular surgery, or macular photocoagulation in the study eye 4. History of intraocular surgery in the study eye within 12 weeks prior to Screening (Visit 1). Yttrium aluminum garnet capsulotomy is permitted if performed >10 weeks prior to Visit 1 5. Have clinically significant cataract that may require surgery during the study period in the study eye 6. Presence of moderate to severe glaucomatous optic neuropathy in the study eye; uncontrolled IOP despite the use of more than two topical agents; a history of glaucoma-filtering or valve surgery is also excluded 7. Axial myopia of greater than -8 diopters in the study eye 8. Have received any investigational product for the treatment of GA within the past 6 months or 5 half-lives (whichever is longer), other than nutritional supplements such as the Age-Related Eye Disease Study (AREDS) formula 9. Have received a gene or cell therapy at any time 10. Have a contraindication to the specified protocol corticosteroid regimen 11. Are unwilling to use two forms of contraception (one of which being a barrier method) for 90 days post-dosing, if relevant 12. Active malignancy within the past 12 months, except for: Appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or prostate cancer with a stable prostate-specific antigen (PSA) =12 months 13. Have any other significant ocular or non-ocular medical or psychiatric condition which, in the opinion of the Investigator, may either put the subject at risk or may influence the results of the study 14. Cohorts 5 to 7 only: presence of metallic objects or implanted stimulator devices in or near the head, including cochlear implants, deep brain stimulators, vagus nerve stimulators, and other implanted electrodes or stimulators

Study Design


Intervention

Biological:
GT005
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
GT005
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
GT005
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
GT005
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor
Device:
GT005/ Device: Orbit™ Subretinal Delivery System
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor Device: Orbit™ Subretinal Delivery System
GT005/ Device: Orbit™ Subretinal Delivery System
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor Device: Orbit™ Subretinal Delivery System
GT005/ Device: Orbit™ Subretinal Delivery System
A recombinant non-replicating Adeno-Associated Viral (AAV) vector encoding a human complement factor Device: Orbit™ Subretinal Delivery System

Locations

Country Name City State
United Kingdom Bristol Eye Hospital Bristol
United Kingdom Moorfields Eye Hospital London
United Kingdom Retina Clinic London London
United Kingdom Manchester Eye Hospital Manchester
United Kingdom Oxford University Hospital Oxford
United Kingdom Sunderland Eye Infirmary Sunderland
United States Ophthalamic Consultants of Boston (OCB) Boston Massachusetts
United States Pepose Vision Institute Chesterfield Missouri
United States Cincinnati Eye Institute Cincinnati Ohio
United States Midwest Eye Institute Indianapolis Indiana
United States Mid-Atlantic Retina Philadelphia Pennsylvania
United States Sierra Eye Associates Reno Nevada
United States Wolfe Eye Clinic West Des Moines Iowa

Sponsors (2)

Lead Sponsor Collaborator
Gyroscope Therapeutics Limited Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of ocular and non-ocular Treatment Emergent AEs (TEAEs) and Treatment-Emergent Serious AEs (TESAEs) Severe Adverse Events (TEAE/TESAE) Proportion of patients with TEAEs/TESAEs after subretinal injection of GT005 240 weeks
Secondary Long-term safety of GT005 at 3 doses Incidence of ocular and non-ocular treatment-emergent AEs (TEAEs) and treatment-emergent serious AEs (TESAEs) up to 240 weeks 240 weeks
Secondary Visual Acuity Change from baseline in BCVA (Best Corrected Visual Acuity) and LLVA (Low Luminance Visual Acuity) score via ETDRS (Early Treatment Diabetic Retinopathy Study) chart 240 weeks
Secondary Macular Sensitivity Change from baseline in macular sensitivity as assessed by mesopic Microperimetry 240 weeks
Secondary Geographic Atrophy Change from baseline in GA size as assessed by fundus autofluorescence 240 weeks
Secondary Rate of successful delivery of Balanced Salt Solution (BSS) or BSS PLUS to the subretinal space (US only) Proportion of subjects with successful delivery of BSS or BSS PLUS to subretinal space Day 1
Secondary Rate of successful delivery of GT005 to the subretinal space (US only) Proportion of subjects with successful delivery of GT005 to subretinal space Day 1
Secondary Incidence of device-related AEs and SAEs (US only) Proportion of subjects with device related AEs and SAEs after subretinal delivery with Orbit SDS Day 1
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT02540954 - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Phase 3
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Completed NCT02510794 - Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Phase 2
Completed NCT02181504 - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration Phase 2
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Terminated NCT02228304 - Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01204541 - A Single-Center Pilot Study to Assess Macular Function N/A
Completed NCT00769392 - Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection N/A
Completed NCT00533520 - Evaluation of Dosing Interval of Higher Doses of Ranibizumab Phase 4
Withdrawn NCT00538538 - Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) Phase 1
Completed NCT00536016 - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Phase 1
Terminated NCT00403442 - Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Phase 1
Recruiting NCT00157976 - Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Phase 3
Completed NCT00211458 - Treatment of Age-Related Macular Degeneration With Anecortave Acetate Phase 2
Completed NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Phase 3
Completed NCT00239928 - Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Phase 2
Completed NCT00095433 - Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT00006202 - Lutein for Age-Related Macular Degeneration Phase 2